PT - JOURNAL ARTICLE AU - Coyle, Peter V. AU - Chemaitelly, Hiam AU - Hadj Kacem, Mohamed Ali Ben AU - Al Molawi, Naema Hassan Abdulla AU - Kahlout, Reham Awni El AU - Gilliani, Imtiaz AU - Younes, Nourah AU - Kanaani, Zaina Al AU - Khal, Abdullatif Al AU - Kuwari, Einas Al AU - Butt, Adeel A. AU - Jeremijenko, Andrew AU - Kaleeckal, Anvar Hassan AU - Latif, Ali Nizar AU - Shaik, Riyazuddin Mohammad AU - Rahim, Hanan F. Abdul AU - Nasrallah, Gheyath K. AU - Yassine, Hadi M. AU - Kuwari, Mohamed G. Al AU - Romaihi, Hamad Eid Al AU - Al-Thani, Mohamed H. AU - Bertollini, Roberto AU - Abu-Raddad, Laith J. TI - SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals AID - 10.1101/2021.01.05.21249247 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.05.21249247 4099 - http://medrxiv.org/content/early/2021/01/06/2021.01.05.21249247.short 4100 - http://medrxiv.org/content/early/2021/01/06/2021.01.05.21249247.full AB - Background Qatar has experienced a large SARS-CoV-2 epidemic. Our first objective was to assess the proportion of the urban population that has been infected with SARS-CoV-2, by measuring the prevalence of detectable antibodies. Our second objective was to identify predictors for infection and for having higher antibody titers.Methods Residual blood specimens from individuals receiving routine and other clinical care between May 12-September 9, 2020 were tested for anti-SARS-CoV-2 antibodies. Associations with seropositivity and higher antibody titers were identified through regression analyses. Probability weights were applied in deriving the epidemiological measures.Results We tested 112,941 individuals (∼10% of Qatar’s urban population), of whom 51.6% were men and 66.0% were 20-49 years of age. Seropositivity was 13.3% (95% CI: 13.1-13.6%) and was significantly associated with sex, age, nationality, clinical-care type, and testing date. The proportion with higher antibody titers varied by age, nationality, clinical-care type, and testing date. There was a strong correlation between higher antibody titers and seroprevalence in each nationality, with a Pearson correlation coefficient of 0.85 (95% CI: 0.47-0.96), suggesting that higher antibody titers may indicate repeated exposure to the virus. The percentage of antibody-positive persons with prior PCR-confirmed diagnosis was 47.1% (95% CI: 46.1-48.2%), severity rate was 3.9% (95% CI: 3.7-4.2%), criticality rate was 1.3% (95% CI: 1.1-1.4%), and fatality rate was 0.3% (95% CI: 0.2-0.3%).Conclusions Fewer than two in every 10 individuals in Qatar’s urban population had detectable antibodies against SARS-CoV-2 between May 12-September 9, 2020, suggesting that this population is still far from the herd immunity threshold and at risk from a subsequent epidemic wave.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors are grateful for support from Hamad Medical Corporation, the Ministry of Public Health, and the Biomedical Research Program, the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar. The statements made herein are solely the responsibility of the authors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the HMC and Weill Cornell Medicine-Qatar Institutional Review Boards.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available within the manuscript and its supplementary materials.